TCGA-A8-A07I-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.470
- G2M_CHECKPOINT+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- MITOTIC_SPINDLE+0.390
- TGF_BETA_SIGNALING+0.360
- IL6_JAK_STAT3_SIGNALING+0.330
- ANGIOGENESIS+0.280
- PROTEIN_SECRETION+0.280
- INFLAMMATORY_RESPONSE+0.270
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.450
- BILE_ACID_METABOLISM-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- FATTY_ACID_METABOLISM-0.280
- WNT_BETA_CATENIN_SIGNALING-0.260
- DNA_REPAIR-0.210
- PEROXISOME-0.200
- KRAS_SIGNALING_DN-0.160
- ADIPOGENESIS-0.150
- MYC_TARGETS_V1-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-6978-01A-11R-1949-07 | — | cohortA1 | 0.883 |
| 2 | TCGA-AR-A250-01A-31R-A169-07 | — | C | 0.862 |
| 3 | MDT-AP-3379 | Med | Medulloblastoma | 0.854 |
| 4 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.836 |
| 5 | TCGA-XF-AAMW-01A-11R-A42T-07 | — | — | 0.833 |
| 6 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.832 |
| 7 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.828 |
| 8 | TCGA-44-7662-01A-11R-2066-07 | — | cohortA1 | 0.822 |
| 9 | TCGA-BH-A1FE-01A-11R-A13Q-07 | — | A | 0.813 |
| 10 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |